Retrospective Study on the Incidence and Management of Anemia in Oncology
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 349
- 试验地点
- 1
- 主要终点
- Incidence of anemia
研究概览
简要总结
The incidence of anemia ranges from 20 to 75% depending on the type of cancer. It is often present at diagnosis and increases with specific treatments. It has an impact on overall survival and quality of life. Its origins are multiple (pure iron deficiency or functional, malnutrition, dyserythropoiesis, insufficiency renal, hemolysis, chemotherapy, radiotherapy, targeted therapies).
Transfusion is the most common treatment offered in the management of anemia. The incidence of anemia and its consequences are often underestimated during cancer management.
Recommendations were published in 2012. An inventory of the incidence of anemia before and after the publication of these recommendations are proposed in order to assess their impact on daily practice.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years old,
- •Follow-up for cancer justifying hospitalization,
- •Presenting anemia defined by a hemoglobin level <11 g / dL,
- •Patient not having objected to the collection of his data after oral and written information.
排除标准
- •patients with a hemoglobin level ≥ 11 g / dL,
- •adult patients under guardianship, curatorship or deprived of liberty,
- •pregnancy or breast-feeding in progress at the time of hospitalization.
结局指标
主要结局
Incidence of anemia
时间窗: 2 years
number of patient with anemia (\<11.0 g/dL) upon admission to hospital on the number of patients hospitalized over the period
次要结局
- Assessment of transfusion prescriptions(2 years)
- Assessment of iron prescriptions(2 years)
- overall survival(2 years)
- Assessment of erythropoiesis stimulating agents (EPO) prescriptions(2 years)
- Time between last transfusion and date of death(2 years)